In this review:
Anti-TNF effectiveness in RA at 1 year
Rheumatic immune-related adverse events of cancer checkpoint therapy
RA recurrence after checkpoint therapy
Predicting successful biological DMARDs tapering
CNTX-4975 for moderate-to-severe OA knee pain
Moderate alcohol intake in gout patients
Nurse- versus GP-led care of gout
Power Doppler ultrasound-detected residual synovitis in RA
Filgotinib phase 2B open-label extension in RA
Meta-analysis of baricitinib 2 mg and 4 mg in RA
Spinal radiographic progression in early ankylosing spondylitis
Please login below to download this issue (PDF)